Dr. Steven E. Shoelson, M.D., Ph.D., served as Clinical Advisors at Diartis Pharmaceuticals, Inc. Dr. Shoelson served as a Clinical Advisor at Versartis, Inc. until June 2010. Dr. Shoelson serves as an Associate Director of Research and Section Head of Cellular & Molecular Physiology at the Joslin Diabetes Center. Dr. Shoelson is Professor of Medicine at Harvard Medical School. He co-founded Catabasis in June 2008. He serves as the Chairman of Scientific Advisory Board at Catabasis Pharmaceuticals, Inc. and Cymabay Therapeutics, Inc. He serves as a Member of Scientific Advisory Board of Metabolex, Inc. and Genmedica Therapeutics S.L. He served as a Member of Scientific Advisory Board at Syndexa Pharmaceuticals Corp. Dr. Shoelson has published over 130 papers, and is considered a leader in the fields of diabetes signal transduction and inflammation in insulin resistance. He won the Diabetes Care Research Award from Boehringer Mannheim and the Juvenile Diabetes Foundation in 1996. He has received numerous awards and honors, including a Burroughs-Wellcome Fund Scholar Award in Experimental Therapeutics, the Excellence in Diabetes Research Award of the Juvenile Diabetes Research Foundation and Boehringer Mannheim Corporation, and a MERIT award from the National Institutes of Health. He also holds the Helen and Morton Adler Chair at the Joslin Diabetes Center. Dr. Shoelson received his Ph.D. in Bioorganic Chemistry from University of Chicago, and M.D. from University of Chicago.

 He aim to identify potential pathophysiological mechanisms contributing to type 2 diabetes, including insulin resistance and β-cell dysfunction, and associated conditions and complications, including hyperuricemia and cardiovascular disease. Studies in the Shoelson lab focus on the pathogenesis of diabetes and its complications, and potential new avenues for treatment.